Medpace Holdings (STU:01P) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:01P Medpace Holdings Inc STU:01P
91 GF Score
Price €531.80
GF Value €469.66
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medpace Holdings  (STU:01P) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Medpace Holdings Cyclically Adjusted PB Ratio Related Terms


Medpace Holdings Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings Cyclically Adjusted PB Ratio Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 12.07 16.35 16.90 24.35

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.28 23.13 26.23 21.95 24.32

STU:01P vs RVTY, CRL, ICLR: Cyclically Adjusted PB Ratio Comparison

For the Diagnostics & Research subindustry, Medpace Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Cyclically Adjusted PB Ratio falls into.


STU:01P
91GF Score
Medpace Holdings Inc STU:01P
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Medpace Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Medpace Holdings's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=13.63/333.9520*333.9520
=13.630

Current CPI (Jun. 2026) = 333.9520.

Medpace Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201609 13.343 241.428 18.457
201612 14.239 241.432 19.696
201703 14.274 243.801 19.552
201706 13.416 244.955 18.290
201709 12.444 246.819 16.837
201712 11.890 246.524 16.107
201803 11.771 249.554 15.752
201806 13.087 251.989 17.344
201809 13.658 252.439 18.068
201812 14.545 251.233 19.334
201903 15.589 254.202 20.480
201906 16.189 256.143 21.107
201909 17.725 256.759 23.054
201912 18.040 256.974 23.444
202003 18.540 258.115 23.987
202006 18.665 257.797 24.179
202009 18.986 260.280 24.360
202012 18.638 260.474 23.896
202103 20.342 264.877 25.647
202106 20.055 271.696 24.650
202109 21.562 274.310 26.250
202112 23.389 278.802 28.016
202203 16.159 287.504 18.770
202206 8.743 296.311 9.854
202209 11.485 296.808 12.922
202212 11.671 296.797 13.132
202303 10.437 301.836 11.548
202306 11.728 305.109 12.837
202309 14.496 307.789 15.728
202312 16.492 306.746 17.955
202403 20.114 312.332 21.506
202406 23.034 314.175 24.484
202409 25.467 315.301 26.973
202412 26.087 315.605 27.604
202503 18.462 319.799 19.279
202506 5.240 322.561 5.425
202509 8.894 324.800 9.145
202512 13.812 324.054 14.234
202603 18.227 330.213 18.433
202606 13.630 333.952 13.630

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Medpace Holdings (STU:01P) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of €531.80 is trading 13.2% above its estimated GF Value™ of €469.66. GuruFocus considers Medpace Holdings to be Modestly Overvalued.

Key valuation signals for STU:01P:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €469.66 vs. price of €531.80 (13.2% above fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the STU:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medpace Holdings Business Description

Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
91GF Score

Get the complete analysis for STU:01P

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€531.80
Price
€469.66
GF Value